News | Radiopharmaceuticals and Tracers | May 17, 2019

Sixty-patient study will assess CellPoint’s Oncardia imaging agent for ability to evaluate presence, severity of coronary artery disease

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company's new one-vial Oncardia (ethylenedicysteine-glucosamine) kits.  The 60-patient trial study is being conducted in the U.S.

Today, slightly greater than 6 million nuclear cardiology perfusion imaging scans are performed in the U.S. annually. Such procedures, referred to as myocardial perfusion imaging (MPI), are performed using either single photon emission computed tomography (SPECT) or positron emission tomography (PET) camera systems. SPECT MPI procedures represent 98 percent of the total. All MPI procedures, regardless of the choice of radiopharmaceutical agent, are designed to illuminate the healthy perfused part of the heart. A high percentage of the patients are required to undergo a time-consuming rest and separate stress study. While there are several cardiovascular disease indicators that can be looked at with MPI, the predominant focus for such studies is the presence, location and severity of myocardial ischemia following a heart attack.  

99mTc-Oncardia is not a perfusion agent. It is being clinically studied as the first functional cardiovascular imaging agent that is target-specific for myocardial ischemia.  One of the clinical objectives of the study is to demonstrate that 99mTc-Oncardia can be effectively used where the patient does not need to be either physically or pharmacologically stressed for the study.

99mTc-Oncardia is for use with SPECT camera systems. CellPoint also is planning to clinically study 68Ga-Oncardia for use with PET camera systems.

For more information: www.cellpointweb.com

Related Content

Feature | Nuclear Imaging

The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics (SPECT, PET)), Therapeutics ...

Time May 26, 2022
arrow
News | Proton Therapy

May 25, 2022 — B dot Medical Inc. and Research Center for Nuclear Physics, Osaka University (RCNP) have conducted a ...

Time May 25, 2022
arrow
News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
Feature | Coronavirus (COVID-19)

Clinical scientists used machine learning (ML) models to explore de-identified electronic health record (EHR) data in ...

Time May 18, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

Time May 13, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
News | Radiology Business

May 12, 2022 — Abbott announced a new partnership with Women as One to launch a new program designed to train more ...

Time May 12, 2022
arrow
News | Radiology Business

May 11, 2022 — Enlitic, a leading AI healthcare company, has welcomed Dave Wilson as the vice president of marketing and ...

Time May 11, 2022
arrow
Subscribe Now